Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03692338 · ClinicalTrials.gov registry record · NA
INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma
A NA study, sponsored by Duke University.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT03692338 is a NA study that was terminated before completion, run by Duke University. The registered enrollment target is 2 participants.
The verdict
NCT03692338, a NA study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study aims to report the effects of immediate or delayed exercise training on patients with advanced or metastatic renal cell carcinoma who are receiving nivolumab and ipilimumab.
Interventions
- BEHAVIORAL Exercise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-11-19 |
| Est. Completion | 2019-12-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03692338
The ClinicalTrials.gov registry entry for NCT03692338 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Exercise is the first listed.
NCT03692338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03692338 about?
NCT03692338 is a clinical study titled "INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma". This study aims to report the effects of immediate or delayed exercise training on patients with advanced or metastatic renal cell carcinoma who are receiving nivolumab and ipilimumab.
What is the current status of trial NCT03692338?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2018-11-19. Estimated completion is 2019-12-09.
What interventions are being tested in trial NCT03692338?
The interventions under investigation include: Exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT03692338?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.